World-Renowned Breast Cancer Oncology and Pathology Experts to Advise Company on the Advancement of its AI-Powered PreciseBreastTM Risk of Recurrence Assessment and Product Portfolio
[November 20, 2024, NEW YORK] — PreciseDx, a leading innovator in AI-powered digital pathology focused on oncology diagnostics, today announced the formation of its Scientific Advisory Board (SAB), comprised of six internationally-recognized experts in breast cancer oncology and pathology. The SAB will work to further the clinical validation and early commercialization of PreciseDx’s PreciseBreastTM risk of recurrence assessment, which provides results in less than 48 hours at a fraction of the current costs. They will also help direct the company’s future product portfolio built on its AI-powered digital pathology platform, combining image analysis with its proprietary Morphology Feature Array® (MFA).
PreciseDx’s platform supports better cancer treatment decisions and outcomes through its MFA, which surfaces highly accurate information by quantifying key characteristics of cancer cells and their relationships to help determine risk and optimal patient management. This technology has proven the ability to enhance pathology interpretation with objective, quantifiable, and highly-accurate data.
PreciseDx has received approval from the New York State Department of Health (NYSDOH) and has begun its Early Access Program (EAP) and initial commercial testing of patient samples.
“We’ve assembled a prestigious group of experts, each with expertise in a critical specialty that supports the advancement of our unique AI-driven platform as we set a new standard in pathology and oncology to optimize patient outcomes,” said Carlos Cordon-Cardo, MD, Ph.D., Co-Founder of PreciseDx, and Chairman of the Advisory Board.
PreciseDx welcomes the following distinguished medical experts to its Scientific Advisory Board:
● Carlos Cordon-Cardo, MD, PhD, Chairman of the Scientific Advisory Board, is a world renowned expert in molecular pathology, laboratory medicine, and systems pathology approach to disease characterization. Dr. Cardon-Cardo is currently the Irene Heinz Given and John LaPorte Given Professor and Chairman for the Mount Sinai Health System Department of Pathology. His academic appointments at Mt. Sinai include Professor and System Chair for Pathology, Molecular and Cell Based Medicine; Professor Genetics and Genomic Sciences; and Professor of Oncological Sciences. Dr. Cordon-Cardo is a co-founder of PreciseDx.
● Kevin Fox, MD, Emeritus Professor CE of Medicine is the former Medical Director of the Rena Rowan Breast Center at the Abramson Cancer Center of the University of Pennsylvania. Dr. Fox held the Mariann T. and Robert J. MacDonald Professorship of Breast Cancer Care Excellence for the Perelman School of Medicine at the University of Pennsylvania. He was professor of medicine at Penn Medicine, earned his medical degree in 1981 from Johns Hopkins University School of Medicine and completed his internship and residency at Johns Hopkins Hospital. He also completed a fellowship in hematology/oncology at HUP. Dr. Fox is a member of the American Society of Clinical Oncology.
● Reshma Mahtani, MD, is Chief of Breast Medical Oncology at Baptist Health South, Miami Cancer Institute. Dr. Mahtani serves as Chief of Breast Medical Oncology at the Miami Cancer Institute, Baptist Health South Florida (Memorial Sloane Kettering affiliate). Dr. Mahtani was an
Associate Professor of Medicine and Co-Leader of the Breast Cancer Program at Sylvester Comprehensive Cancer Center, University of Miami, where she oversaw the clinical trial program across the network. She has served on the ASCO Quality Oncology Practice Initiative (QOPI)
Steering Committee and was a member of the editorial board of The Breast Journal. She is Editor-in-Chief for Practice Update. She has been Program Director for several officially licensed Best of ASCO programs and is the Director of the ASCO Highlights series.
● Joyce O’Shaughnessy, MD, is a medical oncologist that focuses on breast cancer prevention and treatment. She currently holds positions at Baylor University and Baylor Scott and White Health System as well as the US Oncology Network. She is Co-Chair of Breast Cancer Research and Chair of Breast Cancer Prevention Research at Baylor-Sammons Cancer Center and for The USOncology Network and is a member of the Scientific Advisory Board for US Oncology ResearchNetwork. Dr. O’Shaughnessy founded The School of Breast Oncology, a program providing acurriculum-based program focused exclusively on breast cancer clinical management.
● Joseph A. Sparano, MD, FACP, is an internationally-recognized expert in breast cancer management and HIV-associated malignancies. He is the Chief of the Division of Hematology and Medical Oncology at Mount Sinai Health System and Deputy Director of the Tisch Cancer
Institute. Dr. Sparano holds the Ezra M. Greenspan MD Professorship in Clinical Cancer Therapeutics at Mt. Sinai.
● Stuart J. Schnitt, MD, is an internationally-recognized expert in breast pathology. He currently serves as the Chief of Breast Oncologic Pathology for the Dana-Farber/Brigham and Women’sCancer Center, Associate Director of the Dana-Farber Cancer Institute and Brigham and Women’s
Hospital Breast Oncology Program, co-leader of the Dana Farber Harvard Cancer Center BreastProgram, Senior Pathologist at Brigham and Women’s Hospital, and Professor of Pathology atHarvard Medical School. Dr. Schnitt’s research includes the understanding of benign breast diseases and breast cancer, with a focus on risk factors for local recurrence in patients with invasive breast cancer and ductal carcinoma in situ treated with breast conserving therapy, benignbreast disease and breast cancer risk, and stromal-epithelial interactions in breast tumor progression.
About PreciseDx®
Founded in 2020, PreciseDx is leveraging AI-powered digital pathology in oncology diagnostics to predict the risk and recurrence of cancer. Combining AI-image analysis with our Morphology FeatureArray® (MFA), PreciseDx is the first company to use AI and machine learning to reveal unmatched disease insights and accurate, actionable intelligence for more comprehensive decision-making.
PreciseDx has raised $31.5M in Series B funding led by Eventide Asset Management. To learn more, visit PreciseDx on our website and on LinkedIn.
About PreciseBreastTM
PreciseBreastTM is an early-stage invasive breast cancer risk assessment, independent of HER2, hormone, and node status. The AI-powered test utilizes standard H&E pathology slide images. Leveraging millionsof data points, PreciseBreastTM analyzes, correlates, and quantifies those critical features that PredictBreast cancer recurrence and delivers a Risk of Recurrence Score. The test meets the rigorous ClinicalLaboratory Improvement Amendments (CLIA) standards and has passed the Clinical LaboratoryEvaluation Program (CLEP) Assay Validation Review by the New York State Department of Health(NYSDOH)P
DxBR will be available worldwide under the brand name of PreciseBreastTM. For more information, please contact precisebreast@precisedx.ai.
# # #
For media inquiries, please contact:
Audrey Mann Cronin
audrey@manncroninpr.com